دورية أكاديمية
أعرض في EDS

Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting.

التفاصيل البيبلوغرافية
العنوان: Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting.
المؤلفون: Deppe M; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany. markus.deppe@medbo.de., Abdelnaim M; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany., Hebel T; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany., Kreuzer PM; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany., Poeppl TB; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany.; Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany., Langguth B; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany., Schecklmann M; Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany.
المصدر: European archives of psychiatry and clinical neuroscience [Eur Arch Psychiatry Clin Neurosci] 2021 Feb; Vol. 271 (1), pp. 61-67. Date of Electronic Publication: 2020 Jul 09.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9103030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8491 (Electronic) Linking ISSN: 09401334 NLM ISO Abbreviation: Eur Arch Psychiatry Clin Neurosci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer International, c1990-
مواضيع طبية MeSH: Transcranial Magnetic Stimulation*, Depression/*therapy , Lorazepam/*administration & dosage , Lorazepam/*therapeutic use, Depression/drug therapy ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Major/therapy ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome
مستخلص: Background/objectives: Repetitive transcranial magnetic stimulation (rTMS) has been established as an effective therapeutic intervention for the treatment of depression. Preliminary data suggest that the efficacy of rTMS is reduced in patients taking benzodiazepines (BZD). Here, we use real-world data from a large sample to investigate the influence of lorazepam on the effectiveness of rTMS.
Methods: From a retrospective cohort of clinically depressed patients that were treated with rTMS, we compared 176 patients not taking any BZD with 73 patients taking lorazepam with respect to changes in the Hamilton Depression Rating Scale (HRDS).
Results: Both groups improved during rTMS according to HRDS scores, but the amelioration of symptoms was significantly less pronounced in patients taking lorazepam (18% vs. 38% responders in the non-lorazepam group). We could not see any association of intake regimen of lorazepam with response in rTMS.
Conclusion: Our observational study suggests that intake of lorazepam impedes the response to rTMS. The impact of lorazepam and other BZD on rTMS should receive more attention and be further investigated in prospective, hypothesis-based treatment studies to determine causal relationships between medication treatments and outcome. This could lead to specific recommendations for pharmacological treatment for depressed patients undergoing rTMS.
References: Belmaker RH, Agam G (2008) Major depressive disorder. New Eng J Med 358(1):55–68. https://doi.org/10.1056/NEJMra073096. (PMID: 10.1056/NEJMra07309618172175)
Nemeroff CB (2007) The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatry Res 41(3–4):189–206. https://doi.org/10.1016/j.jpsychires.2006.05.008. (PMID: 10.1016/j.jpsychires.2006.05.008)
Lépine J-P, Briley M (2011) The increasing burden of depression. Neuropsychiatr Dis Treat 7(Suppl 1):3–7. https://doi.org/10.2147/NDT.S19617. (PMID: 10.2147/NDT.S19617217506223131101)
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Ärztliches Zentrum für Qualität in der Medizin (ÄZQ) (2015) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression–Langfassung, 2. Auflage. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN); Bundesärztekammer (BÄK); Kassenärztliche Bundesvereinigung (KBV); Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF).
Kessler RC, Berglund P, Demler O et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105. https://doi.org/10.1001/jama.289.23.3095. (PMID: 10.1001/jama.289.23.309512813115)
Pehrson AL, Sanchez C (2015) Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des Devel Ther 9:603–624. https://doi.org/10.2147/DDDT.S62912. (PMID: 10.2147/DDDT.S62912256534994307650)
Reininghaus U, Böhnke JR, Chavez-Baldini U et al (2019) Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). World Psychiatry 18(1):67–76. https://doi.org/10.1002/wps.20607. (PMID: 10.1002/wps.20607306006296313235)
Duman RS, Aghajanian GK, Sanacora G et al (2016) Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22(3):238–249. https://doi.org/10.1038/nm.4050. (PMID: 10.1038/nm.4050269376185405628)
Daly EJ, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75(2):139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739. (PMID: 10.1001/jamapsychiatry.2017.373929282469)
Swainson J, Thomas RK, Archer S et al (2019) Esketamine for treatment resistant depression. Expert Rev Neurother 19(10):899–911. https://doi.org/10.1080/14737175.2019.1640604. (PMID: 10.1080/14737175.2019.164060431282772)
Schatzberg AF, Rush AJ, Arnow BA et al (2005) Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 62(5):513–520. https://doi.org/10.1001/archpsyc.62.5.513. (PMID: 10.1001/archpsyc.62.5.51315867104)
McIntyre RS, Filteau M-J, Martin L et al (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 156:1–7. https://doi.org/10.1016/j.jad.2013.10.043. (PMID: 10.1016/j.jad.2013.10.04324314926)
George MS, Nahas Z, Li X et al (2002) Novel treatments of mood disorders based on brain circuitry (ECT, MST, TMS, VNS, DBS). Semin Clin neuropsychiatry 7(4):293–304. (PMID: 10.1053/scnp.2002.35229)
George MS, Lisanby SH, Avery D et al (2010) Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 67(5):507–516. https://doi.org/10.1001/archgenpsychiatry.2010.46. (PMID: 10.1001/archgenpsychiatry.2010.4620439832)
Levkovitz Y, Isserles M, Padberg F et al (2015) Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 14(1):64–73. https://doi.org/10.1002/wps.20199. (PMID: 10.1002/wps.20199256551604329899)
O'Reardon JP, Solvason HB, Janicak PG et al (2007) Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 62(11):1208–1216. https://doi.org/10.1016/j.biopsych.2007.01.018. (PMID: 10.1016/j.biopsych.2007.01.01817573044)
Lefaucheur J-P, Aleman A, Baeken C et al (2020) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol 131(2):474–528. https://doi.org/10.1016/j.clinph.2019.11.002. (PMID: 10.1016/j.clinph.2019.11.002)
Gaynes BN, Lloyd SW, Lux L et al (2014) Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry 75(5):477–489. https://doi.org/10.4088/JCP.13r08815 (quiz 489). (PMID: 10.4088/JCP.13r0881524922485)
Baeken C, Brem A-K, Arns M et al (2019) Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. Curr Opin Psychiatry 32(5):409–415. https://doi.org/10.1097/YCO.0000000000000533. (PMID: 10.1097/YCO.0000000000000533311451456688778)
Rasmussen KG (2011) Some considerations in choosing electroconvulsive therapy versus transcranial magnetic stimulation for depression. J ECT 27(1):51–54. https://doi.org/10.1097/YCT.0b013e3181da84c6. (PMID: 10.1097/YCT.0b013e3181da84c621343711)
Rossi S, Hallett M, Rossini PM et al (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120(12):2008–2039. https://doi.org/10.1016/j.clinph.2009.08.016. (PMID: 10.1016/j.clinph.2009.08.016198335523260536)
Janicak PG, O'Reardon JP, Sampson SM et al (2008) Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 69(2):222–232. https://doi.org/10.4088/jcp.v69n0208. (PMID: 10.4088/jcp.v69n020818232722)
Abdelnaim MA, Langguth B, Deppe M et al (2019) Anti-suicidal efficacy of repetitive transcranial magnetic stimulation in depressive patients: a retrospective analysis of a large sample. Front Psychiatry 10:929. https://doi.org/10.3389/fpsyt.2019.00929. (PMID: 10.3389/fpsyt.2019.0092931969842)
Mutz J, Vipulananthan V, Carter B et al (2019) Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ (Clinical research ed) 364:1079. https://doi.org/10.1136/bmj.l1079. (PMID: 10.1136/bmj.l1079)
Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the United States. JAMA psychiatry 72(2):136–142. https://doi.org/10.1001/jamapsychiatry.2014.1763. (PMID: 10.1001/jamapsychiatry.2014.176325517224)
Romach M, Busto U, Somer G et al (1995) Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 152(8):1161–1167. https://doi.org/10.1176/ajp.152.8.1161. (PMID: 10.1176/ajp.152.8.11617625464)
Rowntree R, Sweeney J, Crumlish N et al (2018) How do we compare with best practice? A completed audit of benzodiazepine and z-hypnotic prescribing. Ir J psychol Med 35(4):321–324. https://doi.org/10.1017/ipm.2016.24. (PMID: 10.1017/ipm.2016.2430501665)
Hessmann P, Jan Z, Neubauer S et al (2018) Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data. Int Clin Psychopharmacol 33(5):282–289. https://doi.org/10.1097/YIC.0000000000000230. (PMID: 10.1097/YIC.000000000000023029952800)
Hunter AM, Minzenberg MJ, Cook IA et al (2019) Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of major depressive disorder. Brain Behav 9(5):e01275. https://doi.org/10.1002/brb3.1275. (PMID: 10.1002/brb3.1275309419156520297)
Blumberger DM, Vila-Rodriguez F, Thorpe KE et al (2018) Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet 391(10131):1683–1692. https://doi.org/10.1016/S0140-6736(18)30295-2. (PMID: 10.1016/S0140-6736(18)30295-2)
Kaster TS, Downar J, Vila-Rodriguez F et al (2019) Trajectories of response to dorsolateral prefrontal rTMS in major depression: a three-D study. Am J Psychiatry 176(5):367–375. https://doi.org/10.1176/appi.ajp.2018.18091096. (PMID: 10.1176/appi.ajp.2018.1809109630764649)
Kaster TS, Downar J, Vila-Rodriguez F et al (2020) Caution when continuing benzodiazepines during rTMS: response to hunter and leuchter. Am J Psychiatry 177(2):172–173. https://doi.org/10.1176/appi.ajp.2019.19060603r. (PMID: 10.1176/appi.ajp.2019.19060603r32008395)
Caulfield KA, Stern AP (2019) Therapeutic high-frequency repetitive transcranial magnetic stimulation concurrently improves mood and anxiety in patients using benzodiazepines. Neuromodulation. https://doi.org/10.1111/ner.13024. (PMID: 10.1111/ner.1302431368628)
Prasser J, Schecklmann M, Poeppl TB et al (2015) Bilateral prefrontal rTMS and theta burst TMS as an add-on treatment for depression: a randomized placebo controlled trial. World J Biol Psychiatry 16(1):57–65. https://doi.org/10.3109/15622975.2014.964768. (PMID: 10.3109/15622975.2014.96476825430687)
Kreuzer PM, Schecklmann M, Lehner A et al (2015) The ACDC pilot trial: targeting the anterior cingulate by double cone coil rTMS for the treatment of depression. Brain Stimul 8(2):240–246. https://doi.org/10.1016/j.brs.2014.11.014. (PMID: 10.1016/j.brs.2014.11.01425541389)
Frank E, Eichhammer P, Burger J et al (2011) Transcranial magnetic stimulation for the treatment of depression: feasibility and results under naturalistic conditions: a retrospective analysis. Eur Arch Psychiatry Clin Neurosci 261(4):261–266. https://doi.org/10.1007/s00406-010-0137-7. (PMID: 10.1007/s00406-010-0137-720737275)
Cohen J (2013) Statistical power analysis for the behavioral sciences, 2nd edn. Taylor and Francis, Hoboken. (PMID: 10.4324/9780203771587)
Kaiser RH, Andrews-Hanna JR, Wager TD et al (2015) Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72(6):603–611. https://doi.org/10.1001/jamapsychiatry.2015.0071. (PMID: 10.1001/jamapsychiatry.2015.0071257855754456260)
Williams LM (2016) Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3(5):472–480. https://doi.org/10.1016/S2215-0366(15)00579-9. (PMID: 10.1016/S2215-0366(15)00579-9271503824922884)
Drysdale AT, Grosenick L, Downar J et al (2017) Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 23(1):28–38. https://doi.org/10.1038/nm.4246. (PMID: 10.1038/nm.424627918562)
Gold BI, Bowers MB, Roth RH et al (1980) GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 137(3):362–364. https://doi.org/10.1176/ajp.137.3.362. (PMID: 10.1176/ajp.137.3.3627356067)
Sanacora G, Mason GF, Rothman DL et al (1999) Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56(11):1043–1047. https://doi.org/10.1001/archpsyc.56.11.1043. (PMID: 10.1001/archpsyc.56.11.104310565505)
Waagepetersen HS, Sonnewald U, Schousboe A (1999) The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem 73(4):1335–1342. https://doi.org/10.1046/j.1471-4159.1999.0731335.x. (PMID: 10.1046/j.1471-4159.1999.0731335.x10501176)
Hasler G, van der Veen JW, Tumonis T et al (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64(2):193–200. https://doi.org/10.1001/archpsyc.64.2.193. (PMID: 10.1001/archpsyc.64.2.19317283286)
Kugaya A, Sanacora G, Verhoeff NPLG et al (2003) Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT. Biol Psychiatry 54(8):792–799. https://doi.org/10.1016/S0006-3223(02)01788-2. (PMID: 10.1016/S0006-3223(02)01788-214550678)
Price RB, Shungu DC, Mao X et al (2009) Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65(9):792–800. https://doi.org/10.1016/j.biopsych.2008.10.025. (PMID: 10.1016/j.biopsych.2008.10.025190587882934870)
Sanacora G, Gueorguieva R, Epperson CN et al (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61(7):705–713. https://doi.org/10.1001/archpsyc.61.7.705. (PMID: 10.1001/archpsyc.61.7.70515237082)
Sanacora G, Mason GF, Rothman DL et al (2003) Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 160(3):577–579. https://doi.org/10.1176/appi.ajp.160.3.577. (PMID: 10.1176/appi.ajp.160.3.57712611844)
Sanacora G, Mason GF, Rothman DL et al (2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159(4):663–665. https://doi.org/10.1176/appi.ajp.159.4.663. (PMID: 10.1176/appi.ajp.159.4.66311925309)
Dubin MJ, Mao X, Banerjee S et al (2016) Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci 41(3):E37–45. (PMID: 10.1503/jpn.150223)
Hasler G, Neumeister A, van der Veen JW et al (2005) Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 58(12):969–973. https://doi.org/10.1016/j.biopsych.2005.05.017. (PMID: 10.1016/j.biopsych.2005.05.01716043137)
Philip NS, Barredo J, Aiken E et al (2018) Neuroimaging mechanisms of therapeutic transcranial magnetic stimulation for major depressive disorder. Biol psychiatry Cogn Neurosci Neuroimaging 3(3):211–222. https://doi.org/10.1016/j.bpsc.2017.10.007. (PMID: 10.1016/j.bpsc.2017.10.00729486862)
Hadas I, Sun Y, Lioumis P et al (2019) Association of repetitive transcranial magnetic stimulation treatment with subgenual cingulate hyperactivity in patients with major depressive disorder: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2(6):e195578. https://doi.org/10.1001/jamanetworkopen.2019.5578. (PMID: 10.1001/jamanetworkopen.2019.5578311670236551850)
Baeken C, de Raedt R (2011) Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci 13(1):139–145. (PMID: 10.31887/DCNS.2011.13.1/cbaeken)
Darmani G, Ziemann U (2019) Pharmacophysiology of TMS-evoked EEG potentials: a mini-review. Brain Stimul 12(3):829–831. https://doi.org/10.1016/j.brs.2019.02.021. (PMID: 10.1016/j.brs.2019.02.02130837122)
Olsen RW (2018) GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology 136(Pt A):10–22. https://doi.org/10.1016/j.neuropharm.2018.01.036. (PMID: 10.1016/j.neuropharm.2018.01.036294072196027637)
Chen S, Huang X, Zeng XJ et al (1999) Benzodiazepine-mediated regulation of α1, α2, β1–3 and γ2 GABAA receptor subunit proteins in the rat brain hippocampus and cortex. Neuroscience 93(1):33–44. https://doi.org/10.1016/S0306-4522(99)00118-9. (PMID: 10.1016/S0306-4522(99)00118-910430468)
Galpern WR, Miller LG, Greenblatt DJ et al (1990) Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABAA-receptor function. Br J Pharmacol 101(4):839–842. https://doi.org/10.1111/j.1476-5381.1990.tb14167.x. (PMID: 10.1111/j.1476-5381.1990.tb14167.x19648201917851)
Gouzer G, Specht CG, Allain L et al (2014) Benzodiazepine-dependent stabilization of GABA(A) receptors at synapses. Mol Cell Neurosci 63:101–113. https://doi.org/10.1016/j.mcn.2014.10.004. (PMID: 10.1016/j.mcn.2014.10.00425466558)
Impagnatiello F, Pesold C, Longone P et al (1996) Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol Pharmacol 49(5):822–831. (PMID: 8622632)
Pesold C, Caruncho HJ, Impagnatiello F et al (1997) Tolerance to diazepam and changes in GABA(A) receptor subunit expression in rat neocortical areas. Neuroscience 79(2):477–487. https://doi.org/10.1016/s0306-4522(96)00609-4. (PMID: 10.1016/s0306-4522(96)00609-49200730)
Uusi-Oukari M, Korpi ER (2010) Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol Rev 62(1):97–135. https://doi.org/10.1124/pr.109.002063. (PMID: 10.1124/pr.109.00206320123953)
Ziemann U, Hallett M, Cohen LG (1998) Mechanisms of deafferentation-induced plasticity in human motor cortex. J Neurosci 18(17):7000–7007. https://doi.org/10.1523/JNEUROSCI.18-17-07000.1998. (PMID: 10.1523/JNEUROSCI.18-17-07000.199897126686792971)
Ziemann U, Muellbacher W, Hallett M et al (2001) Modulation of practice-dependent plasticity in human motor cortex. Brain 124(Pt 6):1171–1181. https://doi.org/10.1093/brain/124.6.1171. (PMID: 10.1093/brain/124.6.117111353733)
Ferrarelli F, Massimini M, Sarasso S et al (2010) Breakdown in cortical effective connectivity during midazolam-induced loss of consciousness. Proc Natl Acad Sci USA 107(6):2681–2686. https://doi.org/10.1073/pnas.0913008107. (PMID: 10.1073/pnas.091300810720133802)
Sarasso S, Boly M, Napolitani M et al (2015) Consciousness and complexity during unresponsiveness induced by propofol, xenon, and ketamine. Curr Biol 25(23):3099–3105. https://doi.org/10.1016/j.cub.2015.10.014. (PMID: 10.1016/j.cub.2015.10.01426752078)
Premoli I, Castellanos N, Rivolta D et al (2014) TMS-EEG signatures of GABAergic neurotransmission in the human cortex. J Neurosci 34(16):5603–5612. https://doi.org/10.1523/JNEUROSCI.5089-13.2014. (PMID: 10.1523/JNEUROSCI.5089-13.2014247410506608220)
Fitzgerald PB, Daskalakis ZJ, Hoy KE (2020) Benzodiazepine use and response to repetitive transcranial magnetic stimulation in major depressive disorder. Brain Stimul 13(3):694–695. https://doi.org/10.1016/j.brs.2020.02.022. (PMID: 10.1016/j.brs.2020.02.02232289699)
Hunter AM, Leuchter AF (2020) Benzodiazepine Use and rTMS Outcome. Am J Psychiatry 177(2):172. https://doi.org/10.1176/appi.ajp.2019.19060603. (PMID: 10.1176/appi.ajp.2019.1906060332008397)
Gunderson JG, Elliott GR (1985) The interface between borderline personality disorder and affective disorder. Am J Psychiatry 142(3):277–288. https://doi.org/10.1176/ajp.142.3.277. (PMID: 10.1176/ajp.142.3.2772857532)
فهرسة مساهمة: Keywords: Affective disorder; Benzodiazepine; Brain stimulation; Depression; Lorazepam; rTMS
المشرفين على المادة: O26FZP769L (Lorazepam)
تواريخ الأحداث: Date Created: 20200711 Date Completed: 20220113 Latest Revision: 20220113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7867521
DOI: 10.1007/s00406-020-01160-9
PMID: 32648109
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-8491
DOI:10.1007/s00406-020-01160-9